Jefferies Financial Group Inc. cut its stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 50.0% during the 2nd quarter, Holdings Channel reports. The fund owned 25,000 shares of the biotechnology company’s stock after selling 25,020 shares during the period. Jefferies Financial Group Inc.’s holdings in Cerevel Therapeutics were worth $795,000 […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) Director N Anthony Coles sold 61,401 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $25.43, for a total value of $1,561,427.43. Following the completion of the transaction, the director now owns 2,704 shares […]
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.02, Briefing.com reports. During the same period last year, the company earned ($0.66) EPS. Cerevel Therapeutics Stock Performance Shares of CERE stock […]